You are about to leave the Clinical Value website now.

Cancel

Hepatocellular carcinoma surveillance and the emerging role of biomarker-based models

Screenshot 2023 05 16 190532

A/Prof Simone Strasser recently published an independent commentary in the Australian Medical Research and Journal “Research Review”, covering at length topics such as non-alcoholic liver disease as an increasing risk factor, hepatocellular carcinoma surveillance including ultrasound as the current standard of care, the nature of patients who should undergo surveillance, serological biomarkers, and biopsy. Watch the interview with A/Prof Strasser on her thoughts about HCC in Australia….

Singapore Cancer Society – World Health Day Webinar 2022

image 3

Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma

young female practitioner nurse with face protective mask working clinic reception desk

This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC.

Bhatti ABHH, Naz K, Abbas G, Khan NY, Zia HH, Ahmed IN…

PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu

DSC07085 1

In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians in the early detection and overall management of HCC, and his clinical experience with PIVKA-II. …

APASL 2023 Taiwan Symposium

unnamed

Watch the APASL 2023 symposium recording to hear experts share key updates on HCC surveillance, diagnosis, uHCC management and adj HCC systemic treatment. …

Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region

discussing treatment options with colleague 1

A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements….